

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUYI INTERNATIONAL PHARMACEUTICAL COMPANY LIMITED**

**武夷國際藥業有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 1889)

**CLARIFICATION ANNOUNCEMENT**

Reference is made to the announcement of Wuyi International Pharmaceutical Company Limited (the “**Company**”) dated 17 February 2017 (the “**Announcement**”) in relation to resignation of executive director and appointment of executive directors.

The board of directors (the “**Board**”) of the Company noted there is a typographical error in the summary section in the English version of the Announcement and wishes to clarify that the name of one of the executive directors appointed is Ms. Hung Hoi Lan, instead of Ms. Hung Hoi Lam.

Save as disclosed herein, all other contents of both the English and Chinese versions of the Announcement remain unchanged.

By Order of the Board  
**Wuyi International Pharmaceutical Company Limited**  
**Lin Ou Wen**  
*Chairman and Chief Executive Officer*

Hong Kong, 20 February 2017

*As at the date of this announcement, the Board comprises 3 Executive Directors, namely, Mr. Lin Ou Wen (Chairman) and Mr. Chen Cheng Qing and Ms. Hung Hoi Lan, and 3 Independent Non-executive Directors, namely, Mr. Zhang Jie, Mr. Zhang Xue Wen and Mr. Wu Cheng Han.*